Except for the historical information and discussions contained herein, statements in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied.

These include, without limitation, risks that: Avanade and Infusion will not be able to close the transaction in the time period anticipated, or at all, which is dependent on the parties’ ability to satisfy certain closing conditions; the transaction might not achieve the anticipated benefits for Avanade; Avanade’s business could be negatively affected if the company cannot expand and develop its services and solutions in response to changes in technology and client demand; the management consulting, systems integration and technology markets are highly competitive and Avanade might not be able to compete effectively; Avanade’s business could be negatively affected by economic and political conditions and the effects of these conditions on its clients’ business and levels of business activity; Avanade’s work with government clients exposes the company to additional risks inherent in the government contracting process; clients may not be satisfied with Avanade’s services; Avanade could have liability or its reputation could be damaged if it does not protect client data or information systems or if its information systems are breached; Avanade’s business could be negatively affected by legal liability that results from providing its solutions or services; Avanade’s results could be adversely affected if its clients terminate their contracts with the company; liabilities could arise if subcontractors or other third parties with whom the company partners cannot deliver their project contributions on time or at all; Avanade’s results of operations may be adversely affected by the rate of growth in the use of technology in business and the type and level of technology spending by its clients; Avanade’s profitability may suffer if it is not able to maintain favorable pricing rates and utilization rates or if the company cannot control costs; Avanade’s global operations are subject to complex risks, some of which might be beyond its control; Avanade’s business may be adversely affected if it is unable to keep its supply of skills, including those personnel currently employed by Infusion and resources in balance with client demand; Avanade may be unable to achieve its business objectives if the company cannot manage the organizational challenges associated with the scope of its operations; Avanade has only a limited ability to protect its intellectual property rights, and its services or solutions could infringe on the rights of others or it could lose its ability to use the intellectual property of others; Avanade’s ability to attract or retain business may depend on the company’s reputation in the marketplace; loss of the company’s significant corporate relationships with Accenture and Microsoft could reduce its revenue and growth prospects; Avanade has a limited ability to set its own independent strategies, and its business strategy and direction may be dictated by Accenture’s overall business strategy; Avanade relies on Accenture for the majority of its revenue, and the loss of that revenue would have a significant adverse impact on Avanade’s results of operations and may affect its ability to continue to operate; Avanade’s global delivery network relies on Accenture, and the loss of that network would increase Avanade’s operating expenses; Microsoft has certain minority rights, and may exercise those rights to protect its own interests, which may not align with Avanade’s; and Avanade is committed to using Microsoft-related technologies, and the company’s inability to use those technologies would adversely impact its results of operations.

Statements in this press release speak only as of the date they were made, and Avanade undertakes no duty to update any forward-looking statements made in this news release or to conform such statements to actual results or changes in Avanade’s expectations.

Avanade acquires Infusion, strengthening digital transformation capabilities